This forced her family into the cruel arithmetic of public fundraising. In 2021, an investigation by The Guardian found that at least 200 UK families were actively raising over £500,000 each for rare-disease treatments abroad. Less than 15% succeeded. Chisa’s campaign, by mid-2021, was faltering. In May 2021, a breakthrough: a British business consortium, moved by a viral video of Chisa’s older brother reading her a bedtime story about “getting new medicine in a faraway city,” donated £200,000. A week later, a celebrity football match organized by a Premier League player added another £90,000. By July, the total reached £1.1 million. Hope flickered.
If you take one thing from this article, let it be this: when you see a medical fundraising appeal, your donation is never just money. It is a vote against uncertainty. And sometimes, even when the outcome is uncertain, the act of trying is the only thing that separates humanity from despair. If you or someone you know is facing a similar situation in England, resources such as the Rare Disease UK (RDUK) network, the “Just4Children” fund, and the “Tree of Hope” charity offer guidance for ethical medical fundraising.
But medical uncertainty does not vanish with money. A pre-travel assessment in early December 2021 revealed that Chisa’s liver enzymes were dangerously high. The Chicago team said she was no longer a candidate for the gene therapy protocol. The treatment had become uncertain in the worst possible way: unavailable. eng raising funds for chisas treatment uncen 2021
Chisa passed away on December 28, 2021, at her home in England, surrounded by her family. The raised funds, per the family’s statement, were donated to a research charity studying her rare disease so that other children might not face the same impossible journey. Chisa’s story, though heartbreaking, is a case study in the ethics and logistics of medical crowdfunding. The keyword “eng raising funds for chisas treatment uncen 2021” captures a specific moment in time—the intersection of national healthcare limits, parental desperation, donor generosity, and the harsh reality that money cannot always buy a cure.
Moreover, the treatment itself carried no guarantee of success. In their fundraising appeals, Chisa’s parents were transparent: “We cannot promise that this treatment will cure her. But we can promise that without it, she has no chance.” That brutal honesty resonated with donors but also introduced a layer of moral hesitation. Some potential supporters asked: “What if we give £10,000 and she still doesn’t make it?” Charitable fatigue is real, especially when outcomes are uncertain. Unlike countries with mandatory catastrophic health insurance, England’s healthcare system is centralized. The NHS’s Highly Specialised Technologies (HST) program evaluates rare-disease treatments based on cost-effectiveness (measured in QALYs—Quality-Adjusted Life Years). If a treatment costs more than £300,000 per QALY gained, it is almost always rejected. For Chisa’s treatment, the cost per QALY exceeded £1.2 million. The NHS said no. This forced her family into the cruel arithmetic
The family faced an agonizing decision: continue fundraising for a treatment that might no longer work, or pivot to palliative care. They chose to press on. “As long as Chisa is fighting, we fight,” her mother told ITV News in September 2021. By October 2021, the campaign had stalled at £1.45 million. Short by £350,000. The Chicago hospital declined to offer a discount. Desperate, the family launched a last-minute auction, selling heirlooms and even a car donated by a local dealer. On November 15, 2021, they announced they had reached the goal—£1,800,032. The news made the BBC’s local headlines.
or "English raising funds for Chia's treatment uncertain 2021" or a medical fundraising scenario involving a person/place named "Chisa" and an uncertain outcome in 2021. Chisa’s campaign, by mid-2021, was faltering
But uncertainty remained. The treatment center in Chicago required proof of full funding before scheduling. The earliest available slot was January 2022. Chisa’s doctors in London warned that her organ function was deteriorating. In August 2021, a routine scan revealed that the disease had spread to her central nervous system—a development that dramatically reduced the experimental treatment’s projected efficacy.